GE HealthCare Announces Clearance Of Three New Magnetic Resonance Innovation With FDA

GE HealthCare (Nasdaq: GEHC) announced today 510(k) clearance of three new magnetic resonance (MR) innovations with the U.S. Food and Drug Administration (FDA): SIGNA™ Sprint with Freelium™1, a 1.5T sealed magnet MRI system; SIGNA™ Bolt2, an advanced 3T MRI scanner; and SIGNA™ One3, an AI-driven ecosystem of workflow solutions designed to help reduce inefficiencies and support MRI exams from plan to scan and beyond.

The new MRI systems and technology combat some of the most complex challenges facing the radiology landscape from a rising demand in procedures caused by a growing aging population, increase in disease incidences, workforce burnout and sustainability expectations. These regulatory milestones signal a significant step forward in GE HealthCare's multi-year strategy to deliver a new wave of innovation and further differentiate its MR portfolio.